Walleye Trading’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$24.4M Sell
112,000
-62,000
-36% -$13.8M 0.04% 442
2025
Q4
$39.8M Sell
174,000
-71,100
-29% -$16.2M 0.06% 354
2025
Q3
$56.8M Buy
245,100
+69,700
+40% +$14.2M 0.09% 224
2025
Q2
$32.6M Buy
175,400
+43,000
+32% +$7.99M 0.06% 350
2025
Q1
$27.7M Buy
132,400
+34,900
+36% +$6.78M 0.06% 340
2024
Q4
$17.3M Sell
97,500
-22,300
-19% -$4.1M 0.04% 526
2024
Q3
$23.7M Buy
119,800
+62,600
+109% +$11.7M 0.05% 395
2024
Q2
$9.81M Sell
57,200
-40,300
-41% -$6.68M 0.02% 691
2024
Q1
$17.8M Sell
97,500
-64,300
-40% -$11.1M 0.04% 469
2023
Q4
$25.1M Sell
161,800
-89,500
-36% -$13M 0.05% 360
2023
Q3
$37.5M Buy
251,300
+156,400
+165% +$23M 0.1% 188
2023
Q2
$12.8M Sell
94,900
-69,900
-42% -$10.3M 0.04% 462
2023
Q1
$26.3M Sell
164,800
-97,400
-37% -$14.9M 0.06% 295
2022
Q4
$42.4M Buy
262,200
+30,500
+13% +$4.68M 0.12% 161
2022
Q3
$31.1M Buy
231,700
+17,300
+8% +$2.48M 0.09% 206
2022
Q2
$32.8M Sell
214,400
-65,500
-23% -$10M 0.11% 181
2022
Q1
$45.4M Sell
279,900
-90,700
-24% -$13.2M 0.14% 117
2021
Q4
$50.2M Buy
370,600
+252,600
+214% +$29.8M 0.17% 115
2021
Q3
$12.7M Buy
118,000
+5,500
+5% +$628K 0.05% 447
2021
Q2
$12.7M Sell
112,500
-67,800
-38% -$7.64M 0.05% 348
2021
Q1
$19.5M Sell
180,300
-302,254
-63% -$32.3M 0.09% 158
2020
Q4
$51.7M Sell
482,554
-20,456
-4% -$1.97M 0.23% 48
2020
Q3
$44.1M Buy
503,010
+31,454
+7% +$2.96M 0.24% 42
2020
Q2
$46.3M Buy
471,556
+339,756
+258% +$29.9M 0.3% 31
2020
Q1
$10M Sell
131,800
-10,200
-7% -$869K 0.08% 189
2019
Q4
$12.6M Buy
142,000
+58,700
+70% +$4.87M 0.09% 224
2019
Q3
$6.31M Buy
83,300
+6,100
+8% +$418K 0.05% 363
2019
Q2
$5.61M Sell
77,200
-70,100
-48% -$5.51M 0.05% 390
2019
Q1
$11.9M Sell
147,300
-8,800
-6% -$720K 0.09% 201
2018
Q4
$14.4M Buy
156,100
+34,200
+28% +$3.01M 0.11% 156
2018
Q3
$11.5M Buy
121,900
+75,700
+164% +$7.18M 0.06% 286
2018
Q2
$4.28M Buy
46,200
+7,400
+19% +$723K 0.02% 714
2018
Q1
$3.67M Sell
38,800
-62,700
-62% -$6.89M 0.02% 718
2017
Q4
$9.82K Buy
101,500
+33,800
+50% +$3.19M 0.05% 351
2017
Q3
$6.01K Sell
67,700
-276,000
-80% -$21M 0.03% 554
2017
Q2
$24.9K Buy
343,700
+229,200
+200% +$15.4M 0.15% 84
2017
Q1
$7.46K Buy
114,500
+52,100
+83% +$3.28M 0.05% 313
2016
Q4
$3.91M Sell
62,400
-64,800
-51% -$3.96M 0.03% 541
2016
Q3
$8.02M Sell
127,200
-58,100
-31% -$3.76M 0.05% 249
2016
Q2
$11.5M Buy
185,300
+21,200
+13% +$1.29M 0.08% 173
2016
Q1
$9.37M Sell
164,100
-106,700
-39% -$5.95M 0.08% 222
2015
Q4
$16M Buy
270,800
+78,100
+41% +$4.5M 0.16% 106
2015
Q3
$10.5M Buy
192,700
+14,868
+8% +$968K 0.1% 157
2015
Q2
$11.9M Sell
177,832
-67,268
-27% -$4.39M 0.12% 129
2015
Q1
$14.3M Buy
245,100
+195,900
+398% +$11.8M 0.14% 103
2014
Q4
$3.22M Buy
49,200
+27,700
+129% +$1.75M 0.03% 466
2014
Q3
$1.24M Sell
21,500
-1,900
-8% -$105K 0.01% 695
2014
Q2
$1.32K Sell
23,400
-5,300
-18% -$278K 0.02% 643
2014
Q1
$1.48K Sell
28,700
-80,700
-74% -$4.08M 0.02% 627
2013
Q4
$5.78M Buy
109,400
+56,800
+108% +$2.79M 0.06% 246
2013
Q3
$2.35M Buy
52,600
+31,200
+146% +$1.38M 0.02% 486
2013
Q2
$885K Buy
+21,400
New +$936K 0.01% 955

Other funds holding ABBV

Walleye Trading's ABBV Position: Q1 2026 in Review

Walleye Trading reduced its AbbVie (ABBV) stake by 48% in Q1 2026, selling an estimated $8.81M and leaving 42,217 shares worth $9.18M. The position accounts for 0.02% of the portfolio, ranked #833.

Walleye Trading first reported a position in ABBV in Q2 2013 and has held it in 28 quarters since. The position peaked at $18.7M in Q4 2025. 4,076 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • Walleye Trading held 42,217 shares of AbbVie worth $9.18M as of Q1 2026.
  • Walleye Trading sold 39,716 AbbVie shares in Q1 2026, an estimated $8.81M.
  • AbbVie made up 0.02% of Walleye Trading's portfolio in Q1 2026, its #833 holding.
  • Walleye Trading first reported a position in AbbVie in Q2 2013 and has held it in 28 quarters since.
  • Walleye Trading's AbbVie position peaked at $18.7M in Q4 2025.
  • 4,076 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Walleye Trading's 13F filing for Q1 2026, filed 11 May 2026.